Key Benefits:
The Minister of Health and Solidarity,
Given the Social Security Code;
Given the Public Health Code;
In the opinion of the Commission of the Transparency,
Stop:
The list of pharmaceutical specialties refundable to insured persons is modified in accordance with the Provisions set out in the Annex.
The Director General of Health and the Director of Social Security shall be responsible, Each as regards the execution of this Decree, which shall be published and its annex in the Official Journal of the French Republic.
A N N E X E
(9 entries)
I.-The following specialties are listed on the list of reimbursable drugs for social policyholders, for which the insured's participation Is provided for in the first paragraph of Article R. 322-2 of the Code of Social Security.
The only therapeutic indications which are eligible for the care or reimbursement of health insurance are, for the specialities referred to below, Those appearing on the market authorization on the date of publication of this Order:
You can view the table in OJ
No 8 of 10/01/2006 text number 26
II. -The following specialities are listed on the list of reimbursable medicinal products: the following specialities:
The only therapeutic indications which are eligible for care or reimbursement by health insurance are: Listed below, those included in the marketing authorisation at the date of publication of this Order:
You can consult the table in OJ
No 8 of 10/01/2006 text number 26
III. -Registered on the list of drugs refundable to insured persons the following speciality.
The only therapeutic indication that qualifies for the care or reimbursement of the health insurance is, for the speciality concerned Below:
Water-soluble vitamin supplementation to cover daily adult needs in parenteral nutrition.
You can view the table in OJ
No 8 of 10/01/2006 text number 26
Done at Paris, December 29, 2005.
For the Minister and by delegation :By preventing the Director
from Social Security:
The
subdirector of the
funding for the care system,
J.-P. Vinquant
By preventing
from the Director General of Health:
The
policy
policy for health products,
H. Holy Marie